A radioimmunoassay for thyrotrophin releasing hormone (TRH) in human serum is described.
In studies on the physiological and pathophysiological role of TRH in the hypothalamo-pituitary-thyroid axis it is necessary to measure the TRH in body fluid and tissues. It is difficult to measure TRH in the serum by radio¬ immunoassay, because serum inactivates TRH immunoreactivity (Bassiri 8c (BSA) and activated charcoal were pur¬ chased from the Sigma Co. USA. Anti-rabbit-gamma-globulin sheep serum was ob¬ tained from the Dainabbot laboratory, Japan.
2) Anti-TRH antibody Anti-TRH antibody was obtained by the method previously described (Mitsuma et al. 1974 ). This antibody did not cross-react with TRH analogues, amino acids, human pituitary hormones or synthetic LH-RH (Table 1) .
3) Diluent
All specimens were diluted with 0.01 M phosphate buffer 0.15 M NaCl and 0.25°/o BSA (pH 7.5).
4) Preparation of charcoal treated serum
Twenty g of activated charcoal was added to 100 ml of pooled normal human serum. The serum was incubated for 24 h at 4°C and centrifuged at 10 000 g for 30 min to remove charcoal. A tracer dose of TRH-'25I was added to serum before addition of charcoal. The residual TRH-'ZSI ¡n the charcoal treated serum was less than 3 %> of FRH-125I initially added. This charcoal treated serum was used as the TRH free serum.
5) Radioiodination of TRH
The radioiodination of TRH was performed by the method previously described (Mitsuma et al. 1974) . Specific activity was 100-120 Ci/g. We therefore used 5.0 ml of methanol per ml serum for extraction of TRH in this study. Fig. 3 shows a standard curve prepared in charcoal treated serum. A dilu¬ tion curve was constructed from high-TRH serum which after administration of synthetic TRH yielded results parallel to the standard curve (Fig. 3) Changes of immunoreactive TRH levels in the serum during antithyroid drug treatment of hypothyroid patients. BD: TRH levels in the serum were below the limit of detectability.
with primary hypothyroidism immunoreactive TRH levels in the serum were 40 to 400 pg/ml. In pituitary hypothyroid patients immunoreactive TRH levels in the serum were 100 to 600 pg/ml. In two hypothalamic hypothyroid patients immunoreactive TRH levels in the serum were below the limit of detectability in all cases.
Immunoreactive TRH levels in the serum were gradually decreased to those in the normal range during thyroxine substitution in patients with primary hypothyroidism (Fig. 5 ). Fig. 6 shows changes of immunoreactive TRH levels in the serum during antithyroid drug treatment for hyperthyroid patients. Before treatment im¬ munoreactive TRH levels in the serum were below the limit of detectability in all cases. During treatment immunoreactive TRH levels in the serum in¬ creased to 5.0 pg/ml or more in 11 of 14 cases, but in the other 3 cases im¬ munoreactive TRH levels in the serum remained below the limit of detect¬ ability during the observation period.
DISCUSSION

Methodology
The antibody which was used in this study had showed few instances of crossreactivity to some TRH analogues. This indicates that the antibody suf¬ ficiently specific for radioimmunoassay of TRH in serum.
Inactivation of TRH immunoreactivity by serum was confirmed in this study as reported by Bassiri 8c Utiger (1972) 
Clinical
In normal subjects immunoreactive TRH levels in the serum were less than 60 pg/ml. These results were slightly higher than those obtained by Oliver et al. (1974) , who used BAL to prevent the inactivation of TRH immuno¬ reactivity by serum. These differences might be due to differences of the assay systems.
There is no report about TRH levels in the serum of patients with primary, pituitary or hypothalamic hypothyroidism. We observed that immunoreactive TRH levels in serum were high in primary or pituitary hypothyroidism and below the limit of detectability in hypothalmic hypothyroidism. These results suggest that measurement of TRH levels in the serum might be a useful in¬ dicator for the differentiation of hypothyroidism.
Immunoreactive TRH levels in the serum were gradually decreased to the normal range during thyroxine treatment of primary hypothyroidism.
In patients with hyperthyroidism, immunoreactive TRH levels in the serum were below the limit of detectability in all cases. In most hyperthyroid pa¬ tients immunoreactive TRH levels in the serum were increased to 5.0 pg/ml or more during antithyroid drug treatment, but in a few cases the level re¬ mained below the limit of detectability during the observation period. These results might be due to continuous inhibition of TRH secretion in a few hyper¬ thyroid patients even though the thyroid hormone levels in the serum were normal, this assay system may also be too insensitive to detect a lower level of TRH.
The above data suggest that the measurement of TRH levels in the serum is a useful tool for studying the role of TRH in the hypothalamo-pituitarythyroid axis in clinical conditions.
